Evaluation of the efficacy of bexarotene for the management of cutaneous T cell lymphoma

Abstract

Bexarotene is a synthetic retinoic acid agent, which selectively activates retinoid X receptors. It was approved in Japan in April 2016 as a treatment option for cutaneous T cell lymphoma. Hyperlipidemia and hypothyroidism are adverse effects associated with its use and titrating the induction dose is difficult. We administrated the drug to 6 patients diagnosed with cutaneous T cell lymphoma. The clinical effects observed were : 3 patients showed a partial response, 2 showed progression, and 1 showed no change in disease status. We discussed the clinical and the possible adverse effects associated with the use of this agent.[Skin Cancer (Japan) 2017 ; 32 : 249-255]